Archive for the ‘china retractions’ Category
The title of this post isn’t exactly how the one-sided conversation between the editors of Neuropsychiatric Disease and Treatment and a group of researchers went. But it seems likely it was pretty close.
The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.
Guangwen Tang, a rice researcher at Tufts University, landed in hot water in 2012 after her team was accused of feeding Chinese children genetically modified Golden Rice without having obtained informed consent from the parents.
Now, she’s suing both Tufts and the American Journal of Clinical Nutrition, which reportedly is retracting a paper, “ß-carotene in Golden Rice is as good as p-carotene in oil at providing vitamin A to children,” based on the federally funded research, claiming that the retraction would constitute defamation. (That retraction hasn’t happened yet.)
This isn’t the first time we’ve heard the retraction = defamation line. Readers might remember Ariel Fernandez, who threatened to sue us for writing about an expression of concern. Maybe a course on the Streisand Effect should be mandatory for PhD students?
Read the rest of this entry »
Recursive plagiarism? Researchers may have published a duplicate of a study retracted for plagiarism
That appears to be the case in a paper brought to our attention by sharp-eyed reader Vladimir Baulin, whose work was copied in a 2006 paper that Journal of Biological Physics retracted for plagiarism.
But you can’t keep a good thief down: the plagiarizing authors just popped up in a new journal with a Chinese-language version of their retracted paper, that looks an awful lot like a knock-off. Here’s a note from Baulin: Read the rest of this entry »
The article, “Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study,” purported to show that: Read the rest of this entry »
You’ve got to love when an author is willing to detail the specifics of an unhelpful retraction notice.
This May, a paper came out in Journal of Thoracic Diseases about drug-resistant tuberculosis. It was retracted in June, for “some misconduct in the manuscript.”
Here’s the notice:
The article “Application status of MALDI-TOF mass spectrometry in the identification and drug resistance of Mycobacterium tuberculosis” (doi: 10.3978/j.issn.2072-1439.2014.02.19) that appeared on page 512-516 of the May 2014 issue of the Journal of Thoracic Disease needs to be withdrawn due to some misconduct in the manuscript. We are sorry for the inconvenience caused.
Since that’s pretty vague and unhelpful, we reached out to corresponding author Jiayun Liu, who gave us a thorough rundown:
Researchers at Qingdao University have fully retracted a paper originally published in Molecular Medicine Reports with a clear, detailed outline of what went wrong and how they discovered the error.
Here’s the notice for “Generation of induced pluripotent stem cells using skin fibroblasts from patients with myocardial infarction under feeder-free conditions:”